GU Cancer

URCC-21038

Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting

---

NCI 10323

Cancer Moonshot Biobank Research Protocol

---

S2013: I-CHECKIT ***Upcoming Temporary Closure 5/6/24 @ 2pm CST***

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

---

S1931

Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)

---

S1823 (NCT04435756) ***Upcoming Permanent Closure 5/20/24 @ 2pm CST*** Permanent Closure of High Risk Relapse Group on 4/15/22

A Prospective Observational Cohort Study to Assess miRNA 371 For Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors

---

A031803

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

---

A151804

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

---

URCC 18007

Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue

---

A031704 ***Step 1 Temporarily Suspended as of 5/15/24***

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

---

A031702 (Penile Cohort Suspended 3/13/20, Miscellaneous GU Tract Variants Cohort suspended 7/20/20, Small Cell Carcinoma/ Neuroendocrine of the Bladder Cohort suspended 4/21/21, Adenocarcinoma of the Bladder Cohort Closed 11/9/20, Renal Medullary Cohort suspended 6/23/21, Sarcomatoid Renal Cell Carcinoma suspended 8/12/21, Cohort C: Squamous Cell Carcinoma of the Bladder temporarily suspended 4/7/22 )

Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors

---